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(pN1) group of tumors involvement at the
intralobar level is substantially better prog-
nostically than that at the hilar level (as
well as single versus multiple nodes or
stations).
Because this strongly and comprehen-
sively supports the idea that it is correct to
stratify (classify) the pN1 cases according
to the level (intralobar best, hilar worst) in
addition to the number of involved lymph
nodes (one better, more than one worse) we
amicably invite Marra and colleagues to
clarify their position regarding the possible
use of such important information, espe-
cially regarding the opportunities to actu-
ally “stratify for optimization” in terms of
adjuvant and neoadjuvant treatment. In
fact, the discussion of their experience is
mainly focused on the evaluation of such
evidence in comparison to others’ similar
work. Regarding adjuvant treatment, we
have developed a timely consolidated ex-
perience in the adoption of postoperative
radiotherapy in completely resected non–
small cell lung cancers, even in the early
stage.2,3 Moreover we have directly dis-
cussed the Post Operative Radiotherapy
Trialists Group conclusions4 and strongly
support the evidence that modern radio-
therapy, accurately planned and adminis-
tered, can give good results with acceptable
side effects in this class of tumors.
From the report of Marra and col-
leagues,1 we have taken the idea that be-
cause for the best prognostic class pN1
cases any therapeutic effort aimed at the
local control could have significance, mod-
ern radiotherapy could certainly find its
place, especially at the investigational
level. For the worst prognostic class pN1
cases, we agree with Marra and colleagues1
that an attempt at systemic (rather than
local) control is justified. In the setting of
neoadjuvant treatment, we see the point of
view of the Marra and colleagues1 when
they note that it is “promising.” The core
fact in managing patients with N1 disease
in the clinical setting is that it is truly
difficult to obtain a substantially correct
diagnosis of true clinical N1 status. In their
very reported experience, in fact, Marra
and colleagues1 noted a limited (24.5%)
pathologic confirmation rate of clinical N1
assessment. Moreover, when a suspicion of
N1 involvement is present at the clinical
staging, this is rarely histologically or cy-
tologically assessable; thus an induction
treatment planned on the basis of the clin-
ical N1 status alone may still be considered
hazardous. In fact, the best that is currently
done in the ongoing phase III induction
trials for early stage non–small cell lung
cancers is to exclude, when N1 status is
suspected, the involvement of N2 stations
by cervical mediastinoscopy, leaving sub-
stantially uncovered the erroneously clini-
cally upstaged to N1 cases (true N0s). We
would be very grateful if Marra and col-
leagues could disclose and describe their
point of view regarding these issues.
Stefano Margaritora, MD
Alfredo Cesario, MD
Pierluigi Granone, MD
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Reply to the Editor:
We are glad to respond to the questions of
Margaritora and colleagues, as they come
from a thoracic surgical group with an es-
tablished experience in the multimodality
treatment of lung cancer.
The results of our study show that pN1
non–small cell lung cancer (NSCLC) could
not be considered an “early stage” disease,
because as many as 45% of patients at the
time of diagnosis and treatment had occult
disease beyond the boundaries of the lobe
of origin, if we consider that even a locore-
gional recurrence develops outside the
margins of “radical” surgical resection.
Another finding is that N1 NSCLC be-
haves heterogeneously, with two extremes:
a population of patients with hilar lymph
node metastases prognostically comparable
to “limited” N2 disease and, on the other
side, a more favorable subgroup of cases
with N1 disease by direct infiltration of
pulmonary lymph nodes. This difference
involves also the pattern of tumor relapse.
In fact, we have observed rates of cancer
recurrence of 41% at distant sites and of
12% locoregionally for the hilar N1 group
and of 24% and 17%, respectively, for the
N1 group by direct invasion. It is therefore
our opinion that the optimal treatment of all
these patients mandates multimodality ap-
proaches, which should be appropriately
investigated by means of randomized clin-
ical trials.
In the adjuvant setting, in all N1 sub-
groups the risk of distant metastases over-
whelms that of locoregional recurrence.
This evidence represents a rationale to use
systemic therapy (eg, chemotherapy) after
surgical resection, although the role and
effectiveness of adjuvant chemotherapy in
early stage NSCLC are still controver-
sial.1,2 Radiotherapy seems to be less man-
datory, because adequate surgery is able to
achieve long-term local control in as many
as 85% of patients and chemotherapy may
also contribute to reduce locoregional fail-
ures. Nevertheless, the cited phase III study
on patients with N0 NSCLC suggests that
modern radiation therapy improves local
control with an acceptable toxicity.3,4 Fur-
ther randomized trials are needed to define
the role of radiotherapy in N1 NSCLC.
Interesting data could be obtained from the
forthcoming publication of the results of
the International Adjuvant Lung Cancer
Trial (EORTC Trial CT0142), which in
stages I to IIIA NSCLC compares different
adjuvant chemotherapy regimens (cisplatin
plus VP16 or cisplatin plus vinca alkaloids)
against control, with radiotherapy being
optional.
In the neoadjuvant setting, preopera-
tively scheduled chemotherapy, alone or in
combination with radiotherapy, provides
survival advantages in locoregionally ad-
vanced NSCLC, as shown by many clinical
trials.5-7 Phase II studies of patients with
early-stage NSCLC treated with induction
chemotherapy have had encouraging re-
sults, but randomized trials are needed to
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1665
clarify whether a multimodality approach
could protect the patients against tumor
recurrence.
The main problem of designing ran-
domized trials with neoadjuvant treatment
for patients with N1 NSCLC is how to
obtain an accurate lymph node staging with
the available diagnostic tools. Whereas cer-
vical mediastinoscopy is highly sensitive
and specific to exclude N2 as well as N3
status, computed tomographic scan of the
chest does not allow detection of lymph
node metastases in the stations 10 to 14 in
most cases. The simultaneous combination
of positron emission tomography and com-
puted tomographic scan, as well as endo-
scopic ultrasonography, could afford fur-
ther information about N1 nodes but are
not yet considered for routine use. We
agree with Margaritora and coauthors that
is difficult to achieve the histologic or cy-
topathologic assessment of N1 disease and
that more invasive diagnostic procedures
(eg, video-assisted thoracoscopy or thora-
cotomy) are to be considered improper for
routine clinical staging. Therefore, phase
III studies on neoadjuvant chemotherapy or
chemoradiotherapy in early stage NSCLC
could actually be designed only by exclud-
ing patients with N2 and N3 disease and
enrolling patients with true N1 and true N0
disease together.
Alessandro Marra, MD
Georgios Stamatis, MD
Division of Thoracic Surgery and Endoscopy
Ruhrlandklinik
Essen, Germany
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Influence of chromosome 22q11.2
microdeletion on surgical outcome
after treatment of tetralogy of Fallot
with pulmonary atresia
To the Editor:
We read with interest the important article
by Cho and colleagues1 recently published
on the Journal. The article reported the
huge surgical series of patients affected by
pulmonary atresia with ventricular septal
defect (PA-VSD) treated at the Mayo
Clinic during the last 20 years. The analy-
sis of follow-up data and risk factors re-
lated to surgery was extremely accurate,
and the operative results were excellent.
However, we noticed that the authors did
not take into consideration the possible as-
sociation with a genetic syndrome among
the hypothetic risk factors for surgical mor-
tality or morbidity.
The high prevalence of genetic abnor-
malities among patients with PA-VSD,
particularly the chromosome 22q11.2 mi-
crodeletion (Di George or velocardiofacial
syndrome) is well described in the litera-
ture,2-7 including important contributions
from the Mayo Clinic.6,7 Chromosome
22q11.2 microdeletion (del22q) has been
reported in about 40% of patients with PA-
VSD,2 particularly those with major aorto-
pulmonary collateral arteries (MAPCAs)3
and complex loop morphology of the pul-
monary arteries.4,5 The del22q abnormality
has also been related to peculiar perioper-
ative problems after surgery for PA-VSD,
such as persistent airway hyperresponsive-
ness or increased prevalence of infectious
complications.6,7
Among the surgical series of 37 consec-
utive patients with PA-VSD and MAPCAs
surgically treated at our institution between
January 1994 and March 2002 (mean age
39  48 months, range 22 days–13 years,
62% of patients 2 years old or younger),
genetically diagnosed del22q (fluorescence
in situ hybridization test) was present in 15
cases (40%, 95% confidence interval [CI]
24%-56%). Its occurrence did not relate to
any peculiar anatomic phenotype with re-
spect to either pulmonary vascular supply
(mean number of MAPCAs 3.7  1.3 for
15 patients with del22q, vs 3  1.4 for 22
patients without del22q, P not significant,
mean pulmonary arteries/collateral arteries
lung segment perfusion ratio 1.5 1.5 vs 2
 1.9, P not significant) or prevalences of
right aortic arch (53% [n  8] among pa-
tients with del22q vs 36% [n  8] among
patients without del22q, P not significant)
and infundibular atresia (53% [n  8]
among patients with del22q vs 50% [n 
11] among patients without del22q, P not
significant).
Twenty-five patients underwent total
unifocalization8 associated with successful
either primary (n  18) or secondary (n 
2) VSD closure in 80% of cases (20/25,
95% CI 64%-96%). The other 12 received
an intermediate right ventricular outflow
tract reconstruction with eventual second-
stage unifocalization and repair in 11 cases,
accounting for an overall repairability rate
of the disease of 86% (31/36, 95% CI 74%-
98%).
Mortality included 5 in-hospital deaths
(15%, 95% CI 3%-27%), and 1 late death.
Survival at 7-year follow-up was 81%.
Two deaths occurred during the immediate
postoperative course in 2 patients with
del22q; pulmonary vascular disease was
the cause in 1 case and no apparent cause
was found at autopsy in the other. Postop-
erative hospital infections, including 2 fun-
gal pneumonias, 1 fungal endocarditis, and
1 Pseudomonas pneumonia, occurred in 4
patients with del22q. Fungal infections
were always related to a decreased CD4
lymphocyte count on peripheral blood sam-
ples and were responsible for 2 of 3 further
in-hospital deaths. The last in-hospital
death was that of a patient with del22q
whose VSD was left open because of air-
way bleeding. Late death finally occurred
in the case of a patient with del22q who
had sudden airway bleeding early after suc-
cessful second-stage closure of VSD. In
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